BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33960179)

  • 1. Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types.
    Gong Z; Yang Y; Zhang J; Guo W
    Cancer Biol Med; 2021 May; 18(4):1080-91. PubMed ID: 33960179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
    Song Y; Huang J; Liang D; Hu Y; Mao B; Li Q; Sun H; Yang Y; Zhang J; Zhang H; Chen H; Liu H; Zhang S
    Front Oncol; 2020; 10():549777. PubMed ID: 33680909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.
    Dennis MJ; Bylsma S; Madlensky L; Pagadala MS; Carter H; Patel SP
    Front Immunol; 2024; 15():1322187. PubMed ID: 38348036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
    Liu Y; Chen L; Zhang S; Shu Y; Qi Q; Zhu M; Peng Y; Ling Y
    Oncol Lett; 2020 Oct; 20(4):27. PubMed ID: 32774500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
    Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
    Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair gene germline mutations in patients with prostate cancer.
    Fang B; Wei Y; Pan J; Zhang T; Ye D; Zhu Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):133-138. PubMed ID: 37283096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.
    Voutsadakis IA
    Cancer Treat Res Commun; 2023; 36():100746. PubMed ID: 37494750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive genomic characteristics in
    He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
    Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
    Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
    Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
    Lin A; Xu W; Luo P; Zhang J
    Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
    Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
    Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
    Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
    BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
    Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
    Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
    Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
    Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
    Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.